American Association for Cancer Research
10780432ccr200337-sup-236374_2_supp_6398426_qc6gjm.pdf (1.03 MB)

Supplementary Tables from A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy

Download (1.03 MB)
journal contribution
posted on 2023-03-31, 22:14 authored by Carine El Sissy, Amos Kirilovsky, Marc Van den Eynde, Ana-Maria Muşină, Maria-Gabriela Anitei, Alfredo Romero, Florence Marliot, Audelaure Junca, Jérôme Doyen, Bernhard Mlecnik, Nacilla Haicheur, Tessa Fredriksen, Christine Lagorce, Anne Jouret-Mourin, Daniel Leonard, Frédéric Bibeau, Soledad Iseas, Enrique L. Roca, Ana M. Cabanne, Carlos A. Vaccaro, Juan P. Santino, Eduardo Huertas, David Tougeron, Carlos Carvalho, Nuno Figueiredo, Rodrigo O. Perez, Angelita Habr-Gama, Viorel Scripcariu, Jean-Pierre Gerard, Jérôme Galon, Guy Zeitoun, Franck Pagès

Supplementary Tables



No biomarker to personalize treatment in locally advanced rectal cancer (LARC) is currently available. We assessed in LARC whether a diagnostic biopsy-adapted immunoscore (ISB) could predict response to neoadjuvant treatment (nT) and better define patients eligible to an organ preservation strategy (“Watch-and-Wait”). Biopsies from two independent cohorts (n1 = 131, n2 = 118) of patients with LARC treated with nT followed by radical surgery were immunostained for CD3+ and CD8+ T cells and quantified by digital pathology to determine ISB. The expression of immune-related genes post-nT was investigated (n = 64 patients). Results were correlated with response to nT and disease-free survival (DFS). The ISB prognostic performance was further assessed in a multicentric cohort (n = 73 patients) treated by Watch-and-Wait. ISB positively correlated with the degree of histologic response (P < 0.001) and gene expression levels for Th1 orientation and cytotoxic immune response, post-nT (P = 0.006). ISB high identified patients at lower risk of relapse or death compared with ISB low [HR, 0.21; 95% confidence interval (CI), 0.06–0.78; P = 0.009]. Prognostic performance of ISB for DFS was confirmed in a validation cohort. ISB was an independent parameter, more informative than pre- (P < 0.001) and post-nT (P < 0.05) imaging to predict DFS. ISB combined with imaging post-nT discriminated very good responders that could benefit from organ preservation strategy. In the “Watch-and-Wait” cohort (n = 73), no relapse was observed in patients with ISB high (23.3%). ISB predicts response to nT and survival in patients with LARC treated by surgery. Its usefulness in the selection of patients eligible for a Watch-and-Wait strategy is strongly suggested.